Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIDE: Treatment Interrupts Depression Early
NCT05002309Phase 2Recruiting
- Sponsor
- Nova Scotia Health
- Start
- Dec 2021
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluoxetine in major depressive disorder (MDD), sponsored by Nova Scotia Health. Primary endpoints: Severity of depressive symptoms and Proportion of time spent depression free. Started Dec 2021; status: recruiting.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05002309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002309.